$522 Million is the total value of Rhenman & Partners Asset Management AB's 108 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ESRX | Express Scripts Hg Co | $7,636,000 | -99.9% | 111,000 | 0.0% | 1.46% | +17.8% | |
| XNCR | Xencor Inc | $5,922,000 | -99.9% | 225,000 | 0.0% | 1.14% | +29.7% | |
| ARRY | Array BioPharma Inc | $4,835,000 | -99.9% | 550,000 | 0.0% | 0.93% | +57.1% | |
| LBIO | Lion Biotechnologies Inc | $4,518,000 | -99.9% | 650,000 | 0.0% | 0.87% | +1.9% | |
| RVNC | Revance Therapeutics Inc | $4,347,000 | -99.9% | 210,000 | 0.0% | 0.83% | +54.0% | |
| OMCL | Omnicell Inc | $4,018,000 | -99.9% | 118,537 | 0.0% | 0.77% | +6.8% | |
| LH | Laboratory Corp of America Hgs | $3,851,000 | -99.9% | 30,000 | 0.0% | 0.74% | +12.7% | |
| UHS | Universal Health Services Inc B | $3,191,000 | -99.9% | 30,000 | 0.0% | 0.61% | +4.3% | |
| PTLA | Portola Pharmaceuticals Inc | $2,711,000 | -99.9% | 120,805 | 0.0% | 0.52% | +19.3% | |
| FGEN | FibroGen Inc | $2,226,000 | -99.9% | 104,000 | 0.0% | 0.43% | +24.9% | |
| ADMS | Adamas Pharmaceuticals Inc | $2,197,000 | -99.9% | 130,000 | 0.0% | 0.42% | +24.2% | |
| NBIX | Neurocrine Biosciences Inc | $1,548,000 | -99.9% | 40,000 | 0.0% | 0.30% | -7.8% | |
| TTPH | Tetraphase Pharmaceuticals Inc | $1,209,000 | -99.9% | 300,000 | 0.0% | 0.23% | +27.5% | |
| MD | Mednax Inc | $600,000 | -99.9% | 9,000 | 0.0% | 0.12% | +21.1% | |
| TNDM | Tandem Diabetes Care Inc | $503,000 | -100.0% | 234,000 | 0.0% | 0.10% | -66.3% | |
| ADVM | Adverum Biotechnologies Inc | $447,000 | -99.9% | 154,006 | 0.0% | 0.09% | -14.9% | |
| CATB | Catabasis Pharmaceuticals Inc | $361,000 | -99.9% | 100,000 | 0.0% | 0.07% | -29.6% | |
| OCUL | Ocular Therapeutix Inc | $335,000 | -99.9% | 40,000 | 0.0% | 0.06% | +45.5% | |
| CNCE | Concert Pharm Inc | $310,000 | -99.9% | 30,099 | 0.0% | 0.06% | +22.9% | |
| MRTX | Mirati Therapeutics Inc | $238,000 | -99.9% | 50,000 | 0.0% | 0.05% | -11.5% | |
| OREXQ | Orexigen Therapeutics Inc | $209,000 | -99.9% | 120,000 | 0.0% | 0.04% | -36.5% | |
| THLD | Threshold Pharmaceuticals | $89,000 | -99.9% | 201,537 | 0.0% | 0.02% | -22.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-01-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.